Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

June 4, 2021
PresentationTivozanib

ASCO 2021: Temporal Characteristics of Treatment-Emergent Adverse Events and Dose Modifications With Tivozanib and Sorafenib in the Phase 3 TIVO-3 Study of Relapsed or Refractory mRCC

February 11, 2021
PresentationTivozanib

ASGO GU 2021: Q-TWiST analysis of tivozanib versus sorafenib in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study

February 11, 2021
PresentationTivozanib

ASCO GU 2021: Tivozanib in Patients with Advanced Renal Cell Carcinoma (aRCC) who have Progressed After Prior Treatment with Axitinib: Results from TIVO-3

January 15, 2021
PresentationTivozanib

ASCO GI 2021: DEDUCTIVE: a Study of Tivozanib in Combination with Durvalumab in Subjects with Untreated Advanced Hepatocellular Carcinoma; Phase Ib results

September 29, 2020
PublicationTivozanib

TiNivo: Safety and Efficacy of Tivozanib-Nivolumab Combination Therapy in Patients With Metastatic Renal Cell Carcinoma

Authors: L. Albiges, P. Barthélémy, M. Gross-Goupil, S. Negrier, M. N. Needle, B. Escudier. Click here for link to article.

September 13, 2020
PublicationTivozanib

Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma

Authors: Sumanta K. Pal, Bernard J. Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, Daniel Powers, David F. McDermott, Brian I. Rini. Click here for link to article.

1 … 3 4 5 6 7 … 15

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.